Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

被引：0

作者：

Takayuki Iwamoto

Naoki Niikura

Kenichi Watanabe

Takashi Takeshita

Yuichiro Kikawa

Kokoro Kobayashi

Nobutaka Iwakuma

Takuho Okamura

Hiroshi Tada

Shinji Ozaki

Toshitaka Okuno

Uhi Toh

Yutaka Yamamoto

Michiko Tsuneizumi

Hiroshi Ishiguro

Norikazu Masuda

Shigehira Saji

机构：

[1] Kawasaki Medical School Hospital,Breast and Thyroid Surgery

[2] Okayama University Hospital,Breast and Endocrine Surgery

[3] Tokai University School of Medicine,Department of Breast Oncology

[4] Hokkaido Cancer Center,Breast Surgery

[5] Kumamoto City Hospital,Breast and Endocrine Surgery

[6] Kansai Medical University Hospital,Department of Breast Surgery

[7] Saitama Red Cross Hospital,Department of Medical Oncology

[8] Kyushu Medical Center,Breast Center, Department of Breast Surgery

[9] Tohoku University Hospital,Department of Surgery, Division of Breast and Endocrine Surgery

[10] Hiroshima Prefectural Hospital,Department of Gastrointestinal and Breast Surgery

[11] Kobe City Nishi-Kobe Medical Center,Department of Breast Surgery

[12] Kurume University Hospital,Department of Breast Surgery

[13] Kumamoto University Hospital,Department of Breast and Endocrine Surgery

[14] Shizuoka General Hospital,Department of Breast Surgery

[15] Saitama Medical University International Medical Center,Breast Oncology Service

[16] Nagoya University Graduate School of Medicine,Department of Breast and Endocrine Surgery

[17] Fukushima Medical University School of Medicine,Department of Medical Oncology

来源：

Breast Cancer Research and Treatment | 2024年 / 203卷

关键词：

Advanced breast cancer; Palbociclib; Fulvestrant; Cell-free DNA; Window of opportunity;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：225 / 234

页数：9

共 50 条

[1] Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Iwamoto, Takayuki
Niikura, Naoki
Watanabe, Kenichi
Takeshita, Takashi
Kikawa, Yuichiro
Kobayashi, Kokoro
Iwakuma, Nobutaka
Okamura, Takuho
Tada, Hiroshi
Ozaki, Shinji
Okuno, Toshitaka
Toh, Uhi
Yamamoto, Yutaka
Tsuneizumi, Michiko
Ishiguro, Hiroshi
Masuda, Norikazu
Saji, Shigehira
BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 225 - 234
[2] Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review
Li, Junjie
Wang, Zhonghua
Shao, Zhimin
CANCER MEDICINE, 2019, 8 (05): : 1943 - 1957
[3] Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Kim, Jee Hyun
Im, Seock-Ah
Sim, Sung Hoon
Bananis, Eustratios
Huang, Xin
Kim, Hyun Seon
Kim, Sung-Bae
JOURNAL OF BREAST CANCER, 2021, 24 (01) : 97 - 105
[4] Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Burris, Howard A., III
EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 201 - 213
[5] Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer
Boer, Katalin
ONCOTARGETS AND THERAPY, 2016, 9 : 6119 - 6125
[6] Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
Watanabe, Kenichi
Niikura, Naoki
Kikawa, Yuichiro
Oba, Mari
Kobayashi, Kokoro
Tada, Hiroshi
Ozaki, Shinji
Toh, Uhi
Yamamoto, Yutaka
Tsuneizumi, Michiko
Okuno, Toshitaka
Iwakuma, Nobutaka
Takeshita, Takashi
Iwamoto, Takayuki
Ishiguro, Hiroshi
Masuda, Norikazu
Saji, Shigehira
BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (02) : 253 - 263
[7] Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer
Mouabbi, Jason A.
Osborne, C. Kent
Schiff, Rachel
Rimawi, Mothaffar F.
BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (02) : 189 - 201
[8] Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
Kenichi Watanabe
Naoki Niikura
Yuichiro Kikawa
Mari Oba
Kokoro Kobayashi
Hiroshi Tada
Shinji Ozaki
Uhi Toh
Yutaka Yamamoto
Michiko Tsuneizumi
Toshitaka Okuno
Nobutaka Iwakuma
Takashi Takeshita
Takayuki Iwamoto
Hiroshi Ishiguro
Norikazu Masuda
Shigehira Saji
Breast Cancer Research and Treatment, 2023, 199 : 253 - 263
[9] Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer
Qureshi, Zaheer
Altaf, Faryal
Khanzada, Mikail
Zaheer, Zaofashan
Fatima, Eeshal
Bakhtiar, Muhammad
CURRENT PROBLEMS IN CANCER, 2024, 51
[10] Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
Norikazu Masuda
Kenichi Inoue
Rikiya Nakamura
Yoshiaki Rai
Hirofumi Mukai
Shinji Ohno
Fumikata Hara
Yuko Mori
Satoshi Hashigaki
Yasuaki Muramatsu
Takashi Nagasawa
Yoshiko Umeyama
Xin Huang
Hiroji Iwata
International Journal of Clinical Oncology, 2019, 24 : 262 - 273

← 1 2 3 4 5 →